ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

11:00AM-11:50AM: Abstract Number: 1980

Understanding the Relationship Between Illness Perceptions and Self-Efficacy Among Latin Americans with SLE Through the Hablemos De Lupus Facebook Page

Patient Outcomes, Preferences, & Attitudes II: Engagement, Perceptions, & Quality of Life (1978–1982)

11:30AM-1:00PM: Abstract Number: L09

A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

Late-Breaking Abstracts (L06–L11)

11:30AM-1:00PM: Abstract Number: L08

Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)

Late-Breaking Abstracts (L06–L11)

11:30AM-1:00PM: Abstract Number: L06

Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis

Late-Breaking Abstracts (L06–L11)

11:30AM-1:00PM: Abstract Number: L10

Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734

Late-Breaking Abstracts (L06–L11)

11:30AM-1:00PM: Abstract Number: L07

Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial

Late-Breaking Abstracts (L06–L11)

11:30AM-1:00PM: Abstract Number: L11

Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

Late-Breaking Abstracts (L06–L11)

12:00PM-12:50PM: Abstract Number: 1957

A Single Cell Stromal Atlas Identifies Conserved Fibroblast Phenotypes Expanded in the Inflamed Synovium, Lung, Intestine, and Salivary Gland

Genetics, Genomics & Proteomics (1953–1957)

12:00PM-12:50PM: Abstract Number: 2016

Baseline Serum Biomarker Levels Predict Spinal Radiographic Progression in Ankylosing Spondylitis Patients on TNF Inhibitor Therapy

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II (2013–2017)

12:00PM-12:50PM: Abstract Number: 1968

Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development

Osteoarthritis & Joint Biology – Basic Science (1968–1972)

12:00PM-12:50PM: Abstract Number: 1967

Combating Rheumatologist Burnout: Use of Protocol Driven Medication Refill by Pharmacists

Measures & Measurement of Healthcare Quality (1963–1967)

12:00PM-12:50PM: Abstract Number: 1956

Dysregulated Expression of the Long Non-coding RNA, LINC01871, Implicated in Sjögren’s Syndrome Pathogenesis

Genetics, Genomics & Proteomics (1953–1957)

12:00PM-12:50PM: Abstract Number: 1964

Engaging Patients in the Development of a Quality Measure of Functional Status to Improve Care Among Patients with Rheumatoid Arthritis

Measures & Measurement of Healthcare Quality (1963–1967)

12:00PM-12:50PM: Abstract Number: 1954

Genome-wide Association Study of Sjögren’s Syndrome Identifies Ten New Risk Loci

Genetics, Genomics & Proteomics (1953–1957)

12:00PM-12:50PM: Abstract Number: 1971

Gut Microbiome Transplantation from MRL/MpJ Mice Prevents Post-Traumatic Osteoarthritis in C57BL6/J Mice

Osteoarthritis & Joint Biology – Basic Science (1968–1972)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].